Silence Therapeutics Share Discussion Threads

[waterloo01] 27/7/2017 06:21

Arrowhead up 16% yesterday which might account for some of the rise in SLN.

[volsung] 26/7/2017 16:23

Bought a few more in anticipation

[volsung] 26/7/2017 15:56

Hopefully we should see a 52 week breakout which will attract some more interest

[partner] 26/7/2017 13:01

Well i suspect anybody buying in at the last placing at £2:40 a share will now be feeling confident of seeing their money again !!!.

[1gw] 26/7/2017 12:08

According to the advfn / ft numbers, rounded volumes traded have been:

Monday: 70k
Tuesday: 170k
Today: 260k up to noon

Is this just momentum trading or something more interesting? Today's volumes are getting pretty significant.

[gersemi] 26/7/2017 11:47

She's off again

1 v 1

depth to the buy side

16 v 9 (54k v 21k)

130p, easy

[1gw] 26/7/2017 08:25

Certainly an encouraging start with the first batch of AT trades coming in so early.

[1gw] 26/7/2017 07:54

Here's hoping the last 2 days prove to have been the start of a trend in terms of increasing volume and price.

[volsung] 25/7/2017 12:31

What did I tell yiz? This is on a roll now. At least another 20-30% here chartwise.

[gersemi] 25/7/2017 11:31

That's also my understanding but then non-MM orders could almost be anyone..

MM's are off the current price at present...

My thinking is MM's are 'insiders' ie they may know something that ordinary DMA traders don't..but then they could know nowt!

it's a conundrum I still cannot solve though you do get a 'feel' sometimes

What I do know is that the price is rising, the chart looks great and this stock contains value not yet released...so the order book can do what it likes

of course if we have a 'situation' (the order book goes bonkers) then I shall update the thread

[gersemi] 25/7/2017 11:02

The price will trade higher if buyers or prepared to pay higher prices which of course suits sellers as they get a higher price for their stock..

There's buying interest here and matched trades (AT) are executed at higher prices. If selling interest exists then buyers (DMA traders and II who have access to the order book) are only prepared to match a seller at lower prices

Of course you also have off-order book trades execution

the current order book is :

1 v 3 (no MM's but DMA traders)

15 v 10 is the depth of orders (45k v 29k)

so current book skewed to the sell side with the depth skewed to the buy side

My understanding of the book is not that great and at times it can move so quick that watching it can be almost a pointless exercise

the fundamental aim should be buy shares in a company that you believe to be undervalued and has excellent prospects going forward

Sometimes trying to read the book can tempt you into making rash decisions which I am guilty of doing..the price will eventually reflect fundamental value

[1gw] 25/7/2017 10:52

Well it's perhaps not "big" buying yet, but I would guess both yesterday and today someone has put those buy orders onto the order book at high enough prices to take out some of the sell orders that have perhaps been there for a while waiting for higher prices. Or perhaps just that the appearance of buys on the book at higher prices encouraged some sellers to emerge and add to the order book at those prices.

If that is correct then it seems fair to me to describe it as "buying" interest at these higher levels being the "new" factor rather than selling interest.

But does anyone here track L2 and if so can they give a more data-based view?

[callumross] 25/7/2017 10:45

Because all the "buys" are AT trades i.e they are perfectly matching a buyer and seller on the order book!

[pwilk47490] 25/7/2017 10:33

Where did all the stock come from?

There haven't been any big sellers for a very long time. Richard Griffiths still owning his 20+% (At a far higher price than it is today btw!).

[1gw] 25/7/2017 09:45

Looks similar to yesterday - a roughly 50k chunk of shares bought up in a few minutes of AT buying. Let's hope for some follow-through today.

[gersemi] 25/7/2017 09:42

Something's brewing 'ere

[callumross] 24/7/2017 23:29

Haven't seen him post on here for a while. I knew what you meant but old SLN'ers like ourselves are aware of the tens of millions poured into research over the years so if some of this investment comes to fruition through the patent estate then that is still a payback for us long suffering shareholders regardless of the status of the company's own in house drug candidates.

[waterloo01] 24/7/2017 19:13

you know what I mean callumross. How's Eagle these days?

[callumross] 24/7/2017 18:24

But the patents are their "own work" Waterloo!

[waterloo01] 24/7/2017 15:54

'Multiple shots on goal' sends a shiver down the spine of any bio investor and doubly so with SLN (I have a long memory here), regardless the value in the near/medium term isn't in their own work, IMO

[1gw] 24/7/2017 15:48

waterloo - the philosophy as it relates to Silence's own programmes is detailed on page 4 of the annual report:

"We have worked extremely hard at target gene/disease selection, benefiting from the learnings of our competitors, and will continue to add to our pre-clinical programmes providing ‘multiple shots on goal.’ Our company is highly focused on thorough vetting of potential candidates to minimise risk of failure."

[waterloo01] 24/7/2017 15:35

1gwm, "multiple shots on goal" philosophy or put another way scatter gun. Been there before and if that's the approach, I shan't stay long.

[1gw] 24/7/2017 15:25

Well they burnt through £13m of operating expenses in 2016, so they do need a lot of cash to stay in business for a few years ahead of having a reliable revenue stream, particularly if they are going to use some of it buying strategic stakes in other companies.

I tend to agree the end-game may be sale to another company. I wonder if the move on Arrowhead was an attempt to game the Amgen interest in Arrowhead - although how that is impacted by the Arrowhead poison pill move I don't know. Good job Ali knows his chess!

I don't agree that Silence has effectively abandoned its own research. I suspect in Ali's mind the Arrowhead price on offer was just too tempting given his views on the undervaluation of the sector and Arrowhead's place within it. All part of his "multiple shots on goal" philosophy.

From memory I think Arrowhead are due to present a research update in September and Silence have got the Canaccord Genuity session booked (in the US) in August.

I'm currently well down on my investment in Arrowhead (following Silence in), but tempted to buy more ahead of news.

[waterloo01] 24/7/2017 14:35

ANLYM likely to to a deal IMO. It would seem SLN have all but abandoned their own research (as evidenced by CEO RNS and ARWR purchase).

Basically it's all in the patents. I bought back a very small stake about a month ago, when it dropped under £1.00, having been out for some years).

Good (or foolish) to see some of the same posters still here! Go Aut027!